Literature DB >> 29620060

Kidney cancer: Combining targeted and immunotherapy.

Clemens Thoma.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29620060     DOI： 10.1038/nrurol.2018.43

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.

Authors:  Toni K Choueiri; James Larkin; Mototsugu Oya; Fiona Thistlethwaite; Marcella Martignoni; Paul Nathan; Thomas Powles; David McDermott; Paul B Robbins; David D Chism; Daniel Cho; Michael B Atkins; Michael S Gordon; Sumati Gupta; Hirotsugu Uemura; Yoshihiko Tomita; Anna Compagnoni; Camilla Fowst; Alessandra di Pietro; Brian I Rini
Journal:  Lancet Oncol       Date:  2018-03-09       Impact factor: 41.316
  1 in total
  3 in total

1.  The predictive value of the preoperative fibrinogen-albumin ratio on the postoperative prognosis of renal cell carcinoma.

Authors:  Jun Liu; Ying Gan; Haifeng Song; Kun Zhu; Qian Zhang
Journal:  Transl Androl Urol       Date:  2020-06

2.  Exploration of Prognostic Immune-Related Genes and lncRNAs Biomarkers in Kidney Renal Clear Cell Carcinoma and Its Crosstalk with Acute Kidney Injury.

Authors:  Chenxia Juan; Ye Zhu; Yan Zhou; Weiwei Zhu; Xufang Wang; Weiming He; Yan Chen
Journal:  J Oncol       Date:  2022-02-08       Impact factor: 4.375

3.  The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma.

Authors:  Zhixin Wang; Jiaqi Chen; Qianyu Li; Na Li; Jing Yu; Feng Liu
Journal:  J Oncol       Date:  2022-03-24       Impact factor: 4.375
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.